BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 08:29 (1668 d 19:12 ago) – Posting: # 21417
Views: 4,256

❝ I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.


Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at Drugs@FDA.
Similar approach (Don't ask how I know :))

J

Complete thread:

UA Flag
Activity
 Admin contact
23,332 posts in 4,899 threads, 1,660 registered users;
20 visitors (0 registered, 20 guests [including 5 identified bots]).
Forum time: 02:41 CET (Europe/Vienna)

I don’t write drafts.
I write from the beginning to the end,
and when it’s finished, it’s done.    Clifford Geertz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5